化合物 Ro 3306|T2356|TargetMol

Ro-3306
872573-93-8

￥255 1mg 起订

￥593 5mg 起订

￥855 10mg 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 Ro 3306

英文名称：: Ro-3306

CAS号：: 872573-93-8

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.74%

产品类别：: 抑制剂

货号：: T2356

Product Introduction

Bioactivity

名称	Ro-3306
描述	Ro 3306 is a CDK1 inhibitor that inhibits CDK1, CDK1/cyclin B1, and CDK2/cyclin E (Ki=20/35/340 nM) selectively and ATP-competitively. Ro-3306 exhibits antitumor activity, inhibits cell cycle arrest, and induces apoptosis.
细胞实验	Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5 mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.(Only for Reference)
激酶实验	CDK assay: The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185 μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6 μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3 nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
体外活性	方法：卵巢癌细胞 OVCA-429 和 OVCAR-3 用 Ro 3306 (1-2.5 nM) 处理 9 天，使用 crystal violet assay 检测细胞活力。结果：OVCA-429 和 OVCAR-3 细胞在高剂量浓度的 Ro 3306 下长达 9 天的生长速率较低。使用 2.5 µM Ro 3306 处理，OVCA-429 和 OVCAR-3 细胞的生长率在第 9 天分别降低了 75.3% 和 87.7%。[1] 方法：人肿瘤细胞系 HCT116、SW480 和 HeLa 用 Ro 3306 (9 µM) 处理 20 h，使用 Flow cytometry 检测细胞周期。结果：用 Ro 3306 对增殖的人类肿瘤细胞处理 20 h 导致 G2/M 期细胞周期的完全阻断。[2]
体内活性	方法：为检测体内抗肿瘤活性，将 Ro 3306 (4 mg/kg) 和 Cisplatin (4 mg/kg) 腹腔注射给携带卵巢癌肿瘤 OVCAR-3 的 BALB/c nude 小鼠，每四天一次，持续四周。结果：与 Ro 3306 或 Cisplatin 治疗相比，联合治疗有效抑制了肿瘤生长。[1]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 12.5 mg/mL (35.57 mM) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1.25 mg/mL (3.56 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately.
关键字	Cyclin dependent kinase \| Ro3306 \| Inhibitor \| Apoptosis \| CDK \| Ro 3306 \| inhibit \| Ro-3306
相关产品	L-Glutamic acid \| Metronidazole \| 5-Fluorouracil \| Dextran sulfate sodium salt (MW 4500-5500) \| Stavudine \| Tributyrin \| Myricetin \| Sorafenib \| L-Ascorbic acid \| Acetylcysteine \| Salicylic acid \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 经典已知活性库 \| 已知活性化合物库 \| 抗胰腺癌化合物库 \| 激酶抑制剂库 \| 抗衰老化合物库 \| TGF-β/Smad靶点化合物库 \| 糖代谢化合物库 \| 酪氨酸激酶分子库 \| 疼痛相关化合物库

Ro-3306|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务